Investor Presentation Q1-Q3 2020
45
Investor presentation First nine months of 2020
The global GLP-1 market penetration varies across regions with
Novo Nordisk having a best-in-class portfolio
GLP-1 market growth and Novo Nordisk market share
GLP-1 value and patient share¹ of the total diabetes market
70%
60%
25%
24%
57.7%
20%
20%
47.6%
50%
40%
38.6%
15%
30%
10%
20%
5%
10%
0%
0%
World
14%
Thi
7%
5%
7%
2%
Aug
2017
Aug
2020
NN market share
Market growth
NN share of growth
NN growth
America
■GLP-1 value share of total diabetes
■GLP-1 patient share of total diabetes
North
EMEA
Region
China
ROW
Source: 1Patient share based on data for the USA, the UK, Germany and France only. IQVIA MAT value, Aug 2020; EMEA: Europe, Middle East, Africa; RoW: Rest of World
Novo NordiskⓇView entire presentation